<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332201</url>
  </required_header>
  <id_info>
    <org_study_id>PMR-EC-1501</org_study_id>
    <secondary_id>2010-019859-21</secondary_id>
    <nct_id>NCT01332201</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®</brief_title>
  <official_title>A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-term Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of tacrolimus blood levels in adults who have received a transplant and are taking
      either Prograf or Advagraf anti-rejection therapy immediately following surgery. This is
      followed by checking of safety and effectiveness for one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine steady state systemic exposure (AUC 0-24h)</measure>
    <time_frame>Day 1, Day 3, Day 7 and Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine Cmax (maximum concentration)</measure>
    <time_frame>Day 1, Day 3, Day 7 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine tmax (time to attain Cmax)</measure>
    <time_frame>Day 1, Day 3, Day 7 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine C24 (concentration prior to next morning dose)</measure>
    <time_frame>Day 1, Day 3, Day 7 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe rejection episodes</measure>
    <time_frame>up to 58 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe subject survival</measure>
    <time_frame>up to 58 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe graft survival</measure>
    <time_frame>up to 58 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Lung Transplantation</condition>
  <condition>Pancreas (Including SPK) Transplantation</condition>
  <arm_group>
    <arm_group_label>Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf</intervention_name>
    <description>oral</description>
    <arm_group_label>Advagraf</arm_group_label>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
    <other_name>tacrolimus modified release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf</arm_group_label>
    <other_name>tacrolimus</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must receive first oral dose of tacrolimus one day (lung, pancreas or Simultaneous
             Pancreas Kidney (SPK) recipients) or three days (heart recipients) after
             transplantation (skin closure)

          -  negative pregnancy test prior to enrolment (females)

          -  agree to practice effective birth control during the study

          -  treated since transplantation with Antithymocyte globulin/ Mycophenolate
             Mofetil/steroids (ATG/MMF/steroids), gastric motility resumed and renal function
             adequate (&lt;230 µmol/l (&lt;2.6 ml/dl)) on Day 1

        Exclusion Criteria:

          -  receiving a multi-organ transplant (with the exception of SPK) or previously received
             an organ transplant (including re-transplantation)

          -  pulmonary vascular resistance ≥4 Wood units despite medication

          -  required an emergency ventricular assist device within one week prior to
             transplantation

          -  significant renal impairment

          -  significant liver disease

          -  malignancies or a history of malignancy within the last 5 years

          -  significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting,
             active upper gastrointestinal disorder that may affect the absorption of tacrolimus,
             or active peptic ulcer

          -  requires systemic immunosuppressive medication for any other indication than
             transplantation

          -  diagnosis of cystic fibrosis

          -  pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140641 in the JapicCTI-RNo. field</description>
  </link>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019859-21/results</url>
    <description>Link to results on EudraCT</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>June 12, 2015</last_update_submitted>
  <last_update_submitted_qc>June 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advagraf</keyword>
  <keyword>Heart</keyword>
  <keyword>Lung</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Transplant</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

